KR900013986A - 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도 - Google Patents
종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도 Download PDFInfo
- Publication number
- KR900013986A KR900013986A KR1019900003932A KR900003932A KR900013986A KR 900013986 A KR900013986 A KR 900013986A KR 1019900003932 A KR1019900003932 A KR 1019900003932A KR 900003932 A KR900003932 A KR 900003932A KR 900013986 A KR900013986 A KR 900013986A
- Authority
- KR
- South Korea
- Prior art keywords
- monoclonal antibody
- antibody according
- mab
- monoclonal
- bound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 450nm에서 측정한 다양한 혈청 표본의 흡광도 결과이다.
제2도는 490nm에서 측정한 MAb Ca 19-9의 흡광도 결과이다.
Claims (12)
- 표 7,8,9 또는 10에 제시된 변이 도메인을 각각 갖는 모노클로날 항체(MAbs) A,B,C 또는 D에 의해 결합되는 에피토프.
- 제1항에 따른 에피토프에대한 모노클로날 항체.
- 표 7,8,9, 또는 10에 제시된 변이 도메인을 함유하는 모노클로날 항체.
- 제3항에 있어서, 변이 도메인 외에 사람 항체 골격을 함유하는 모노클로날 항체.
- 제3항에 있어서, 항원-결합 서열 외의 변이 도메인이 사람의 기원인 모노클로날 항체.
- 제3항에 있어서, 변이영역 외에 쥐의 항체 골격을 함유하는 모노클로날 항체.
- 제2 내지 6항 중 어느 한 항에 있어서, 약제로서의 모노클로날 항체.
- 제2 내지 6항 중 어느 한 항에 있어서, 진단 보조제로의 모노클로날 항체.
- 제2 내지 6항 중 어느 한 항에 따른 모노클로날 항체 및 불활성 부형제를 함유하는 치료학적 조성물.
- 제2항 내지 6항 중 어느 한 항에 따른 모노클로날 항체 또는 이의 반응부위를 일부로서 함유하는 분자작제물.
- 제10항에 있어서, 효소 또는 방사성 표지물이 결합된 분자 작제물.
- 제10항에 있어서, 독소, 촉매, 항체, 다양한 V-유전자 특이체의 조합물, MHC계열 I 또는 계열 II 항원, 또는 세포 용해 성분이 결합된 분자 작제물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3909799A DE3909799A1 (de) | 1989-03-24 | 1989-03-24 | Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung |
DE39097994 | 1989-03-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900013986A true KR900013986A (ko) | 1990-10-22 |
KR100189046B1 KR100189046B1 (ko) | 1999-06-01 |
Family
ID=6377161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900003932A KR100189046B1 (ko) | 1989-03-24 | 1990-03-23 | 종양-관련 항원에 대한 모노클로날 항체의 가변성 도메인의 폴리펩타이드 |
Country Status (12)
Country | Link |
---|---|
US (3) | US6926896B2 (ko) |
EP (3) | EP0727435B1 (ko) |
JP (1) | JP3043772B2 (ko) |
KR (1) | KR100189046B1 (ko) |
AT (3) | ATE140486T1 (ko) |
AU (1) | AU628948B2 (ko) |
CA (1) | CA2012993C (ko) |
DE (4) | DE3909799A1 (ko) |
DK (3) | DK0727436T3 (ko) |
ES (3) | ES2090052T3 (ko) |
GR (1) | GR3020610T3 (ko) |
PT (1) | PT93536B (ko) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989011296A1 (en) * | 1988-05-17 | 1989-11-30 | Raychaudhuri, Syamal | Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen |
DE3909799A1 (de) * | 1989-03-24 | 1990-09-27 | Behringwerke Ag | Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6610299B1 (en) | 1989-10-19 | 2003-08-26 | Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
DE4106389A1 (de) * | 1991-02-28 | 1992-09-03 | Behringwerke Ag | Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung |
US7241595B2 (en) | 1989-10-20 | 2007-07-10 | Sanofi-Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
DE4033120A1 (de) * | 1990-10-18 | 1992-04-23 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von chimaeren antikoerpern |
DE4133791A1 (de) * | 1991-10-11 | 1993-04-15 | Behringwerke Ag | Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung |
DE4225853A1 (de) * | 1992-08-05 | 1994-02-10 | Behringwerke Ag | Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung |
US6030797A (en) * | 1992-10-08 | 2000-02-29 | Dade Behring Marburg Gmbh | Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof |
GB9525180D0 (en) * | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
US5905027A (en) * | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
MXPA03001643A (es) * | 2000-08-24 | 2004-05-14 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
JP2011520914A (ja) | 2008-05-15 | 2011-07-21 | トランスモレキュラー, インコーポレイテッド | 転移腫瘍の処置 |
CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
HUE034119T2 (en) | 2010-02-04 | 2018-01-29 | Morphotek Inc | Chlorotoxin polypeptides and conjugates and their use |
WO2011142858A2 (en) | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
WO2011144744A1 (en) | 2010-05-20 | 2011-11-24 | Therapharm Gmbh | Targeted radioactive compound for human cd66 for the treatment of disorders |
BR112015013525A2 (pt) | 2012-12-10 | 2017-11-14 | Hutchinson Fred Cancer Res | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
EP3351271A1 (en) | 2017-01-23 | 2018-07-25 | TheraPharm GmbH | Radioimmunoconjugate for use in treating bone marrow associated diseases |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1193378A (en) | 1967-04-11 | 1970-05-28 | Rand Dev Corp | Cancer Antigen Complexes |
US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US4349528A (en) | 1979-11-21 | 1982-09-14 | The Wistar Institute | Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen |
US4460561A (en) | 1980-03-03 | 1984-07-17 | Goldenberg M David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4582797A (en) | 1980-09-25 | 1986-04-15 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins |
US4446240A (en) | 1981-01-30 | 1984-05-01 | Nerenberg Samuel T | Pancreas specific protein systems |
US4522918A (en) | 1981-12-15 | 1985-06-11 | Jeffery Schlom | Process for producing monoclonal antibodies reactive with human breast cancer |
US4612282A (en) | 1981-12-15 | 1986-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Monoclonal antibodies reactive with human breast cancer |
JPH0811075B2 (ja) | 1982-06-30 | 1996-02-07 | 雄治 松岡 | 単クローン性抗cea抗体 |
US4485093A (en) | 1982-08-13 | 1984-11-27 | Runge Richard G | Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer |
EP0118365B1 (en) | 1983-03-04 | 1990-08-29 | Health Research, Inc. | Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy |
US4579827A (en) | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
US4569788A (en) | 1983-05-18 | 1986-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies against non small cell lung cancer |
US4677058A (en) | 1983-05-19 | 1987-06-30 | Karl Tryggvason | Detecting malignant cells with monoclonal antibodies specific to type IV collagenase enzyme |
US6294172B1 (en) * | 1983-08-12 | 2001-09-25 | Dade Behring Marburg Gmbh | Monoclonal antibodies with specificity for membrane-associated antigens |
DE3531301A1 (de) | 1985-09-02 | 1987-03-05 | Behringwerke Ag | Monoklonale antikoerper gegen tumorassoziierte glykoproteine, verfahren zu ihrer herstellung sowie ihre verwendung |
DE3416774A1 (de) | 1984-05-07 | 1985-11-14 | Behringwerke Ag, 3550 Marburg | Monoklonale antikoerper, verfahren zu ihrer herstellung sowie ihre verwendung |
DE3329184A1 (de) * | 1983-08-12 | 1985-02-21 | Behringwerke Ag, 3550 Marburg | Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene |
EP0145373B1 (en) * | 1983-11-23 | 1992-03-25 | The Ohio State University Research Foundation | Purification of cancer-associated protein and preparation of antibody thereto |
US4585742A (en) | 1983-12-14 | 1986-04-29 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibody with specificity to human small cell carcinoma and use thereof |
NZ210867A (en) | 1984-01-31 | 1989-01-06 | Litton Bionetics Inc | Tumour-specific monoclonal antibodies, production thereof and use |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4645828A (en) | 1984-03-23 | 1987-02-24 | Oncogen | Platelet related growth regulator |
DE3586216T2 (de) | 1984-05-01 | 1992-12-10 | Ciba Corning Diagnostics Corp | Brusttumorassoziiertes antigen und monoklonale antikoerper dazu. |
US4683200A (en) | 1984-05-17 | 1987-07-28 | Setsuo Hirohashi | Monoclonal antibody to human cancer antigen and method for producing same |
JPS6144900A (ja) * | 1984-08-08 | 1986-03-04 | Green Cross Corp:The | モノクロ−ナル抗体及び癌抗原検出用試薬 |
US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
CA1339798C (en) | 1985-02-01 | 1998-04-07 | Alan N. Houghton | Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans |
US5169939A (en) * | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
WO1988002117A1 (en) * | 1986-09-19 | 1988-03-24 | Scripps Clinic And Research Foundation | Monoclonal paratopic molecule directed to human ganglioside gd2 |
IL84285A (en) * | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
DK554886A (da) * | 1986-11-19 | 1988-07-18 | Novo Industri As | Antistoffer |
US4810781A (en) * | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
US5204244A (en) * | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
EP0365209A3 (en) * | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
ES2052027T5 (es) * | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
DE3909799A1 (de) * | 1989-03-24 | 1990-09-27 | Behringwerke Ag | Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung |
US5580774A (en) * | 1989-07-31 | 1996-12-03 | Eli Lilly And Company | Chimeric antibodies directed against a human glycoprotein antigen |
-
1989
- 1989-03-24 DE DE3909799A patent/DE3909799A1/de not_active Withdrawn
-
1990
- 1990-03-21 EP EP96100442A patent/EP0727435B1/de not_active Expired - Lifetime
- 1990-03-21 ES ES90105322T patent/ES2090052T3/es not_active Expired - Lifetime
- 1990-03-21 AT AT90105322T patent/ATE140486T1/de not_active IP Right Cessation
- 1990-03-21 ES ES96100442T patent/ES2116789T3/es not_active Expired - Lifetime
- 1990-03-21 DK DK96100443T patent/DK0727436T3/da active
- 1990-03-21 EP EP90105322A patent/EP0388914B1/de not_active Expired - Lifetime
- 1990-03-21 DK DK90105322.3T patent/DK0388914T3/da active
- 1990-03-21 EP EP96100443A patent/EP0727436B1/de not_active Expired - Lifetime
- 1990-03-21 ES ES96100443T patent/ES2116790T3/es not_active Expired - Lifetime
- 1990-03-21 AT AT96100443T patent/ATE166883T1/de not_active IP Right Cessation
- 1990-03-21 DK DK96100442T patent/DK0727435T3/da active
- 1990-03-21 DE DE59010826T patent/DE59010826D1/de not_active Expired - Lifetime
- 1990-03-21 AT AT96100442T patent/ATE166882T1/de not_active IP Right Cessation
- 1990-03-21 DE DE59010418T patent/DE59010418D1/de not_active Expired - Lifetime
- 1990-03-21 DE DE59010825T patent/DE59010825D1/de not_active Expired - Lifetime
- 1990-03-22 PT PT93536A patent/PT93536B/pt not_active IP Right Cessation
- 1990-03-23 AU AU52150/90A patent/AU628948B2/en not_active Expired
- 1990-03-23 JP JP2075340A patent/JP3043772B2/ja not_active Expired - Lifetime
- 1990-03-23 KR KR1019900003932A patent/KR100189046B1/ko not_active IP Right Cessation
- 1990-03-23 CA CA002012993A patent/CA2012993C/en not_active Expired - Lifetime
-
1994
- 1994-12-13 US US08/356,791 patent/US6926896B2/en not_active Expired - Fee Related
-
1996
- 1996-07-24 GR GR960401970T patent/GR3020610T3/el unknown
-
2004
- 2004-09-17 US US10/942,929 patent/US20060159682A1/en not_active Abandoned
-
2008
- 2008-02-07 US US12/068,545 patent/US7662383B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0727436A1 (de) | 1996-08-21 |
DE3909799A1 (de) | 1990-09-27 |
AU628948B2 (en) | 1992-09-24 |
AU5215090A (en) | 1990-11-08 |
JP3043772B2 (ja) | 2000-05-22 |
EP0388914A1 (de) | 1990-09-26 |
ATE140486T1 (de) | 1996-08-15 |
CA2012993C (en) | 2001-07-03 |
PT93536A (pt) | 1990-11-07 |
DK0388914T3 (da) | 1996-11-04 |
EP0727435A1 (de) | 1996-08-21 |
GR3020610T3 (en) | 1996-10-31 |
ES2116790T3 (es) | 1998-07-16 |
DE59010825D1 (de) | 1998-07-09 |
DE59010418D1 (de) | 1996-08-22 |
US20060159682A1 (en) | 2006-07-20 |
KR100189046B1 (ko) | 1999-06-01 |
DK0727436T3 (da) | 1999-02-01 |
US6926896B2 (en) | 2005-08-09 |
DK0727435T3 (da) | 1999-02-01 |
DE59010826D1 (de) | 1998-07-09 |
US20020068056A1 (en) | 2002-06-06 |
US7662383B2 (en) | 2010-02-16 |
ES2116789T3 (es) | 1998-07-16 |
ATE166882T1 (de) | 1998-06-15 |
CA2012993A1 (en) | 1990-09-24 |
ATE166883T1 (de) | 1998-06-15 |
ES2090052T3 (es) | 1996-10-16 |
EP0727436B1 (de) | 1998-06-03 |
EP0727435B1 (de) | 1998-06-03 |
PT93536B (pt) | 1996-03-29 |
JPH032200A (ja) | 1991-01-08 |
US20090246132A1 (en) | 2009-10-01 |
EP0388914B1 (de) | 1996-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900013986A (ko) | 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도 | |
NO984136D0 (no) | Humanisert kimært antistoffmolekyl for bruk som dianostikum, og diagnostisk preparat omfattende et slikt antistoffmolekyl | |
KR900005995A (ko) | 변형 인터류킨-2 및 그의 제조방법 | |
KR930702029A (ko) | 동종접합된 면역 글로불린 | |
BR9106232A (pt) | Molecula de anticorpo recombinante,cadeia pesada humanizada,cadeia leve,sequencia de dna,vetor de clonagem,celula hospedeira,processos para produzir um anticorpo e um produto de anticorpo,e uma composicao terapeutica,composicao terapeutica,processo para terapia ou diagnose e processo para o tratamento de homens e animais | |
KR910700350A (ko) | Il-2수용체의 p_55 tac 단백질에 대해 특이적인 키메릭 면역글로블린 | |
ES2051897T3 (es) | Genes clonados que codifican proteinas de fusion ig-cd4 y su uso. | |
KR950005327A (ko) | 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자 | |
KR960706560A (ko) | 인화 항체 및 이것의 사용 방법(humanized antibodies and uses thereof) | |
ES2100174T3 (es) | Nuevos anticuerpos reactivos con carcinomas humanos. | |
ES2102007T3 (es) | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. | |
KR910002897A (ko) | 에리트로포이에틴(epo)펩타이드 및 이에 대한 항체 | |
DE69531290D1 (de) | Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen | |
BR0208676A (pt) | anticorpo monoclonal quimérico, linhagem celular, composição farmacêutica, e, uso de um anticorpo monoclonal | |
ATE154613T1 (de) | Monoklonaler antikörper spezifisch für ein humanes atherom-assoziiertes antigen | |
DE69932812D1 (de) | Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe | |
ES2173910T3 (es) | Anticuerpos humanizados dirigidos contra el antigeno a33. | |
KR920006005A (ko) | 인체 IgE에 대한 모노클론 항체 | |
ATE123952T1 (de) | Vernetzte antikörper und verfahren zu ihrer herstellung. | |
KR940006602A (ko) | 면역글로불린 이소타입에 대한 재조형 모노클로날 항체 | |
DE68921360D1 (de) | Monoklonale Antikörper von Mäusen gegen das gp41 Protein von menschlichem Immunmangelsyndrom-Virus. | |
DK0466818T3 (da) | Monoklonalt antistof der genkender et glycoprotein fra mucin-antigen fra membranen af fedtkugler fra human mælk | |
KR880001815A (ko) | 슈도모나스 에루기노사 편모에 대한 단일클론항체 | |
KR870700023A (ko) | 녹농균의 E8Ag항원 및 그것에 대한 모노클로날 항체및 하이브리도마 | |
Boguslawski et al. | Improved procedure for preparation of F (ab′) 2 fragments of mouse IgGs by papain digestion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20111223 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20121226 Year of fee payment: 15 |
|
EXPY | Expiration of term |